

Additional file 7. The number of missing data for study outcomes

	Assessment period ^a	Group ^b (n = 88)			
		Group A (n = 22)	Group B (n = 24)	Group C (n = 20)	Group D (n = 22)
GMFM	Baseline	0	0	0	0
	1 month	0	0	0	1
	3 months	0	0	0	0
	6 months	0	0	0	0
	12 months	1	2	0	2
GMPM	Baseline	0	0	0	0
	1 month	0	0	0	1
	3 months	0	0	0	0
	6 months	0	0	0	0
	12 months	1	2	0	2
BSID-II Mental scale raw score	Baseline	0	0	0	0
	1 month	0	0	0	1
	3 months	0	0	0	0
	6 months	0	0	0	0
	12 months	1	2	0	2
BSID-II Motor scale raw score	Baseline	0	0	0	0
	1 month	0	0	0	1
	3 months	0	0	0	0
	6 months	0	0	0	0
	12 months	1	2	0	2
DTI	Baseline	0	0	1 ^c	0
	12 months	2 ^c	3 ^c	1 ^c	2 ^c
PET/CT	Baseline	0	0	0	2
	12 months	2	3+(5) ^c	0	2+(5) ^c
EEG	Baseline	0	2	0	0
	12 months	2	2+(2) ^c	0	2+(1) ^c
Cytokine ELISA^d	D-4	7	6	3	5
	D-0	7	6	3	5
	D+3	7	6	4	5
	D+10	7	6	3	5
	D+30	7	6	6	5
Cytokine RT-PCR^d	D-4	7	6	3	5
	D-0	7	6	3	5
	D+3	7	6	3	5
	D+10	7	6	4	5
	D+30	7	6	6	5

^aAssessment periods are each months after intervention. ^bGroup A (n = 22) received UCB and EPO, group B (n = 24) received UCB and placebo EPO, group C (n = 20) received placebo UCB and EPO, and group D (n = 22) received placebo UCB and placebo EPO. ^cnumbers are the missing data who refused or failed to perform the evaluation, and the numbers in the parenthesis are ones that could not be appropriately processed through the software programs. ^dCytokine analyses were performed from blood samples collected at 4 days before UCB injection (D-4), at the day of and prior to UCB injection (D-0), and 3, 10, and 30 days after UCB injection (D+3, D+10, and D+30, respectively).

Abbreviations: BSID-II, Korean version of the Bayley scales of infant development, second edition; DTI, diffusion tensor image; GMPM, gross motor performance measure; GMFM, gross motor function measure; PET/CT, positron emission tomographic/computed tomography; EEG, electroencephalogram; ELISA, enzyme linked immunosorbent assay; RT-PCR, reverse transcription polymerase chain reaction